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BACKGROUND
Enterobacter aerogenes is a motile, non-spore forming, Gram-negative bacteria from the
Enterobacteriaceae family. Enterobacter spp. have emerged as multidrug-resistant (MDR)
nosocomial bacteria, especially in intensive care units (Loiwal et al., 1999; Piagnerelli et al., 2002).
Therefore, over the last decade Enterobacter spp. were included in the ESKAPE group, which
also comprises Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, and Pseudomonas aeruginosa (Rice, 2008; Boucher et al., 2009). Further, bloodstream
infections with MDR E. aerogenes have been associated with high mortality rates (Davin-Regli and
Pagés, 2015).
Hospital outbreaks due to E. aerogenes have been reported in Europe since the mid-1990s
and have been related to an epidemic extended-spectrum beta-lactamase (ESBL) clone carrying
the blaTEM-24 gene (Bosi et al., 1999; Galdbart et al., 2000; Dumarche et al., 2002; Salso et al.,
2003). Constitutive AmpC a (beta-lactamase) overexpression is the major cephalosporin resistance
mechanism in Enterobacter spp., happening more often than the acquisition of ampC genes
through the activity of mobile genetic elements (Perez-Perez and Hanson, 2002). Further, the
increased expression of ESBLs led to the adoption of carbapenems to treat E. aerogenes infections
(Perez-Perez and Hanson, 2002; Davin-Regli and Pagés, 2015).
Carbapenems have been considered the antibiotic of choice for treating patients infected
with ESBL-producing Enterobacteriaceae (Vardakas et al., 2012). However, emergence of
carbapenem-resistant E. aerogenes isolates during carbapenem therapy of hospitalized patients
(Chen et al., 2008), cases of sepsis due to carbapenem-resistant E. aerogenes after liver
transplantation (Chen et al., 2009) and hospital disseminations of carbapenemase-producing
E. aerogenes have been recently reported in several countries (Lavigne et al., 2013; Kuai et al., 2014;
Qin et al., 2014; Pulcrano et al., 2016). Acquisition and expression of carbapenemases constitute
the primary mechanism underlying the development of carbapenem resistance (Rapp and Urban,
2012). Nevertheless, loss of function mutations in porin genes and increased expression of eﬄux
pumps or their regulators have also been associated with carbapenem resistance profiles (Pradel
and Pages, 2002; Yigit et al., 2002; Bornet et al., 2003).
Broad-spectrum antimicrobial-resistant E. aerogenes isolates, some resistant to carbapenems
(Qin et al., 2014) and last-line therapeutic options such as colistin (Diene et al., 2013),
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have been responsible for outbreaks in the United States of
America (Wong et al., 2010), China (Qin et al., 2014), Japan
(Goshi et al., 2002), France (Diene et al., 2013), Fiji (Narayan
et al., 2009) and Brazil (Tuon et al., 2015). However, few
reports related to E. aerogenes epidemiology, pathogenesis,
and molecular characterization have been conducted in Brazil.
Recently, five panresistant E. aerogenes isolates were reported
in a Brazilian teaching hospital, resulting in a high mortality
rate (37.5%) among 16 infected patients (Tuon et al., 2015).
We have observed high prevalence (>20%) of ESBL-producing
Enterobacteriaceae spp., in particular K. pneumoniae and E.
aerogenes, in our hospital since 2003 (Nogueira Kda et al., 2014,
2015). Previous molecular characterization studies conducted
over 5 years in our hospital showed high prevalence of blaCTX-M2,
-M15, -M59, blaSHV-2 and blaTEM genes in Enterobacter spp.
isolates (Nogueira Kda et al., 2014, 2015). The presence of
blaPER-2 was also detected in a few isolates (Nogueira Kda
et al., 2014, 2015). Given the severity of E. aerogenes infections
and the urgent need to better understand the genetic basis
of multidrug resistance, here we report the whole-genome
sequencing and resistance gene repertoire of four multidrug-
resistant E. aerogenes isolated from hospitalized patients in Brazil.
METHODS
Sample Collection and Identification
E. aerogenes isolates C10, D2, D3, and E9 were obtained between
2006 and 2012 from patients hospitalized in wards or intensive
care units at the Hospital de Clínicas of the Universidade
Federal do Paraná (Curitiba, Brazil). The main selection criterion
for genome sequencing was the MDR phenotype, particularly
in carbapenem resistant isolates. The negative laboratory tests
for carbapenemases were also taken into account, as divergent
enzymes or alternative resistance mechanisms could be relevant
to the observed MDR phenotypes. C10 and D2 samples were
isolated from different body sites of the same patient. Isolates
were grown in selective medium with an ertapenem disk (10
ug) and stored at −80◦C in trypticase soy broth containing
glycerol 15%. Identification of isolates was performed using
Vitek R© 2 Compact (BioMérieux S.A., Marcy l’Etoile, France) and
by mass spectrometry using Microflex LT instrument (Bruker
Daltonics, Bremen, Germany). This study was carried out in
accordance with the Brazilian legislation and was approved by
the Institutional Ethics Review Board of the Hospital de Clínicas,
Universidade Federal do Paraná (IRB#: 2656.263/2011-11). Our
study involved only bacterial isolates and no human specimens
were analyzed or stored. Further, we used no patient information
other than the anatomical sites from where the isolates were
collected. Therefore, the same Ethics Review Board exempted us
from obtaining informed consent forms.
Resistance Profile Analysis
Antimicrobial Susceptibility Testing
Isolates were tested by agar dilution against 15 antibiotics
according to the Clinical and Laboratory Standard Institute
guidelines (CLSI, 2015a). Minimal inhibitory concentration
(MIC) was interpreted as recommended by CLSI standards
(CLSI, 2015b). Polymyxin, tigecycline and fosfomycin
breakpoints were interpreted using EUCAST standards (Eucast,
2016). Modified Hodge test (MHT), double-disk synergy and
hydrolysis assay were performed to determine the carbapenem
resistance phenotypes, as previously described (Carvalhaes et al.,
2010; Eucast, 2013).
Molecular Typing and Detection of Resistance
Markers
The genetic relatedness of the E. aerogenes isolates were
determined by pulsed-field gel electrophoresis (PFGE), as
described elsewhere (Kaufmann, 1998). DNA fingerprints
were interpreted as recommended by Tenover et al. (1995).
The presence of the blaMOX, blaCMY, blaLAT, blaBIL,
blaDHA, blaACC, blaMIR, blaACT, blaFOX, blaTEM, blaSHV,
blaCTX-M1, -M2, -M8, -M9, -M25, blaKPC, blaGES, blaIMP, blaVIM,
blaNDM, blaSPM, blaGIM, blaSIM, blaOXA-23, -48, -51, -58, and
-143 was tested by PCR as previously described (Payne and
Thomson, 1998; Poirel et al., 2000, 2011; Perez-Perez and
Hanson, 2002; Naas et al., 2008; Higgins et al., 2009; Woodford,
2010; Nordmann et al., 2011).
Genome Sequencing, Assembly, and
Annotation
Genomic DNA was extracted using DNeasy 96 Blood &
Tissue Kit (QIAGEN Silicon Valley, Redwood City, USA).
DNA quality was assessed using a Bioanalyzer 2100 system
(Agilent Technologies, Santa Clara, USA). DNA quantification
was performed using Qubit (Thermo Fisher Scientific Inc.,
Waltham, USA). Illumina sequencing libraries with an average
fragment size of 550 bp were prepared using Illumina TruSeq
DNA PCR-free LT Kit (Illumina Inc., San Diego, USA). Whole-
genome sequencing of paired-end (PE) libraries was performed
using a HiSeq 2500 instrument in RAPID run mode (Illumina
Inc., San Diego, USA) at the Life Sciences Core Facilities of
the State University of Campinas (São Paulo, Brazil). Quality-
based trimming and filtering was performed using Trimmomatic
version 0.32 (Bolger et al., 2014). PE reads were assembled de
novo using Velvet version 1.2.10 (Zerbino and Birney, 2008) and
contigs were scaffolded using SSPACE version 3.0 (Boetzer et al.,
2011). Gene predictions and annotations were performed using
NCBI Prokaryotic Genome Automatic Annotation Pipeline
(PGAAP; Angiuoli et al., 2008).
Identification of Antibiotic Resistance
Genes
Antibiotic resistance-related genes were predicted using the
ResFinder database version 2.1 (Zankari et al., 2012) with the
following parameters: “all databases” were used for antimicrobial
configuration, type of reads as “assembled genomes/contigs” and
thresholds of 98 identity and 80% coverage between sequences.
This dataset of resistance genes was complemented with
BLASTp searches against the ARDB (Antibiotic Resistance Genes
Database) version 1.1 (Liu and Pop, 2009) using “resistance gene
complete” database, 40% identity and e-value of 0.0001.
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RESULTS
Resistance Profiles
All isolates showed MDR profile and had increased MIC for at
least one carbapenem. Information regarding collection date and
site, clinical setting, PFGE profile and antimicrobial resistance
profiles of each isolate are available in Table 1. Among the four
analyzed samples, C10 and D2 were isolated from different
body sites of the same patient within a short period of time (a
month) and belong to the same PFGE profile. These genomes
allow one to analyze the possible genome plasticity between the
isolates. D3 and E9 samples were isolated from two patients with
an interval of collection date greater than 5 years. D3 and E9
were also interesting because of their sensitivity to meropenem
and resistance to ertapenem and imipenem. Surprisingly, E9
showed resistance to carbapenems but not to 3rd (ceftazidime
and cefotaxime) and 4th generation (cefepime) cephalosporins
(Table 1). All isolates possessed blaAmpC and blaTEM, as detected
by PCR. The gene blaCTX-M2 was found in all isolates except
E9. Phenotypic tests (i.e., Modified Hodge test and double-disk
synergy) to detect carbapenemases were positive for C10, D2, and
E9. However, no class A, B, andD carbapenemase encoding genes
were detected by PCR. All isolates tested negative in carbapenem
hydrolysis assays.
Genomic Features
We obtained between 16,841,714 and 25,138,390 150 bp PE reads
per library. After genome assembly, 5,833,521 bp were assembled
TABLE 1 | Clinical, phenotypic, molecular data, and genomic features of the four Enterobacter aerogenes isolates reported in the present work.
Sample ID E. aerogenes C10 E. aerogenes D2 E. aerogenes D3 E. aerogenes E9
CLINICAL DATA
Date of isolation 09.28.2007 10.12.2007 12.12.2006 01.31.2012
Clinic Ward Ward Ward ICUb
Source Blood Catheter tip BALa Urine
MINIMAL INHIBITORY CONCENTRATION (mg/L)
Amicacin 64 64 64 64
Gentamicin >64 >64 >64 2
Ceftazidime 16 32 16 0.5
Cefepime 128 >128 128 0.5
Cefotaxime >128 128 128 0.5
Ertapenem 32 32 16 2
Imipenem 8 8 32 8
Meropenem 8 8 2 0.5
Polimyxin 0.25 0.25 0.5 0.25
Ciprofloxacin >16 >16 16 2
Levofloxacin >8 8 >8 0.25
Tigecycline 2 2 1 0.5
Doxycycline 16 16 64 8
Minocycline 8 8 8 2
Fosfomycin 256 256 >512 64
MOLECULAR FEATURES
PFGE profile A A1 B C
bla genes blaAmpC, blaTEM,blaCTX−M2 blaAmpC, blaTEM, blaCTX−M2 blaAmpC, blaTEM,blaCTX−M2 blaAmpC, blaTEM
GENOMIC FEATURES
Estimate genome size (bp) 5,833,521 5,821,782 5,584,745 5,637,471
Genome coverage 208x 182x 137x 197x
Number of scaffolds 58 57 55 59
N50 (bp) 505,999 464,022 505,714 461,836
Number of paired-end reads used 14,346,552 12,939,780 9,406,438 12,891,456
%GC 53.61 53.63 53.69 53.67
Predicted genes 5,636 5,622 5,311 5,402
Predicted protein-coding genes 5,363 5,380 5,067 5,129
tRNAs 82 80 83 85
rRNAs (5S, 16S, 23S) 9, 5, 16 6, 3, 8 8, 4, 9 8, 10, 13
ncRNAs 12 12 13 12
Pseudogenes 149 133 127 145
Numbers in bold indicate resistance to a given antibiotic. aBronchoalveolar lavage (BAL) and b Intensive care unit (ICU).
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in 58 scaffolds for C10, 5,821,782 bp were assembled in 57
scaffolds for D2, 5,584,745 bp were assembled in 55 scaffolds for
D3 and 5,637,471 bp were assembled in 59 scaffolds for E9. By
using the NCBI Prokaryotic Annotation Pipeline, we were able to
predict 5,363, 5,380, 5,067, and 5,129 protein-coding sequences in
each of the genomes listed above, respectively. Genomic features
of the four sequenced genomes are summarized in Table 1.
Antibiotic Resistance Genes
A total of 18 enzymes related to antibiotic resistance were
identified using ResFinder, ARDB and PGAAP (Table 2). All
isolates harbor genes related to: (i) aminoglycoside resistance
(genes aacA4 and aadA); (ii) beta-lactam resistance, including
genes belonging to class A beta-lactamases (TEM family), class
B beta-lactamases (Ribonuclease Z), class C beta-lactamases
(CMY/LAT/MOX/ACT/MIR/FOX family) and class D beta-
lactamases (OXA-9); (iii) bacitracin resistance (gene bacA), and
(iv) sulphonamide resistance (gene sul1; Table 2). Genes sul2 and
rmtD were only identified in E. aerogenes D3. The gene sul2 has
been implicated on sulphonamide resistance for inducing high
expression levels of the enzyme dihydropteroate synthase (Sköld,
2001), while rmtD has been related to aminoglycoside resistance
and this variant was identified for the first time in South America
in a P. aeruginosa isolate in 2005 (Doi et al., 2007). Interestingly,
E. aerogenes D3 was isolated in 2006, indicating that this variant
has spread amongst Enterobacteriaceae in Brazil since its first
report (Doi et al., 2007).
Although the four isolates showed carbapenem-resistance, no
carbapenemase gene was identified using molecular detection
or in silico analysis. Hence, it is likely that these isolates
employ alternative mechanisms to counter carbapenem effects.
Various multidrug eﬄux transporters were found in the genomes
described here (Table 2). They belong to four superfamilies:
the major facilitator superfamily (MFS), multidrug and toxic
compound extrusion (MATE), ATP-binding cassette (ABC)
and resistance-nodulation-cell division (RND). RND type of
transporters has been often associated with multidrug resistance
of Gram-negative bacteria (Nikaido, 1998). In particular, the
RND type genes forming the AcrA-AcrB-TolC eﬄux pump were
found in multiple copies in our isolates (Table 2). Experimental
evolution studies of E. aerogenes under successive imipenem
exposure reported alterations in membrane permeability with
complete loss of porins (e.g., Omp35 and Omp36) and
overexpression of AcrAB-TolC eﬄux pumps (Bornet et al., 2003;
Thiolas et al., 2005; Lavigne et al., 2012). As a result of eﬄux
pump expression, the E. aerogenes isolates showed resistance to
carbapenems and other antibiotics, especially fluoroquinolones
(Bornet et al., 2003; Thiolas et al., 2005; Lavigne et al., 2012).
Given the multiple copies of genes encoding eﬄux pumps in
our isolates, it is possible that an increased expression of AcrAB-
TolC eﬄux pumps could contribute to the observed carbapenem-
resistant profiles.
E. aerogenes is an emergent nosocomial pathogen with a
diversity of mechanisms to circumvent antimicrobial activity.
Here we reported the phenotypic screens, genome sequencing,
and prediction of putative resistance gene repertoires of four
multidrug-resistant E. aerogenes isolated between 2006 and 2012.
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The data reported here may help understand the biochemistry,
evolution, and epidemiology of this important pathogen. The
material provided in this workmay be used in future comparative
genomics and molecular epidemiology studies aiming to clarify
the resistance profiles and dynamics of multidrug-resistant
Enterobacteriaceae species.
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